HBEAG LOSS AND SEROCONVERSION PREDICTORS BY BASELINE CLINICAL FEATURES AND VIRAL DEEP SEQUENCING OF TREATMENT WITH TENOFOVIR ALAFENAMIDE FUMARATE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER 144 WEEKS
Gastroenterology（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要